Last reviewed · How we verify
NCT06269874: ASPERA-ANOCA
Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment
NA trial testing microvascular function assessment in Microvascular Coronary Artery Disease in 40 participants. Not yet recruiting.
31 July 2027
Quick facts
| Lead sponsor | Johannes Gutenberg University Mainz |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | diagnostic |
| Enrollment | 40 |
| Start date | 2 March 2027 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 August 2027 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- microvascular function assessment
Conditions studied
- Microvascular Coronary Artery Disease — all drugs for Microvascular Coronary Artery Disease →
Sponsor
Johannes Gutenberg University Mainz
Who can join
18 and older, any sex, with Microvascular Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate the agreement and reproducibility between intravenous and intracoronary adenosine administration during invasive assessment of microvascular function. Goals of this study are: 1. Agreement and reproducibility between intravenous and intracoronary adenosine administration in the IMR (Index of microvascular resistance) value. 2. Agreement and reproducibility of FFR(fractional flow reserve), CFR (coronary flow reserve), MRR (microvascular resistance reserve), RRR (resistive reserve ratio) and reproducibility of each of these as compared with CFRabs (absolute coronary flow). 3. Time required for IMR measurements
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06269874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Microvascular Coronary Artery Disease
Currently open trials in the same condition.
- NCT05492110 — Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microva · NA · recruiting
- NCT04541797 — Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozi · NA · active not recruiting
- NCT04827498 — Myocardial Ischemia Without Obstructive Coronary Stenoses · recruiting
Other Johannes Gutenberg University Mainz trials
Trials by the same sponsor.
- NCT07076511 — A Novel Intuitive Airway Trolley for Quick Decision-making in Simulated Unexpected Difficult Airway Situations: Evaluati · NA · completed
- NCT06739993 — Effects of Autonomic Nervous System Modulation by Heart Rate Variability Biofeedback Training With Resonant Frequency Br · NA · recruiting
- NCT06514495 — Differential Effects of in Vivo and Virtual Exposure Therapy in Agoraphobia · NA · recruiting
- NCT07460791 — Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years · recruiting
- NCT06479083 — Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson's Network · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06269874 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johannes Gutenberg University Mainz
- Last refreshed: 8 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06269874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing